Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

This research is being done to find out if Carboplatin and Taxane works better alone or when
given with an experimental drug called MORAb-003(farletuzumab) in subjects with first
platinum sensitive relapsed ovarian cancer.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language


end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003953
  •   2012/11/30
  •   2009/02/13
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT00849667  (
  •   MORAb003-004  (Morphotek)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Ovarian Cancer
  •   C56 -  Malignant neoplasm of ovary
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: MORAb-003 (farletuzumab)
  •   Drug: MORAb-003 (farletuzumab)
  •   Drug: 0.9% Saline
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, caregiver, investigator/therapist, assessor
  •   Placebo, Active control
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Progression-free survival using by RECIST; time frame: 3 years

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Overall Survival, CA-125 PFS, GCIG PFS, Length of first versus second remission, Tumor Response,Serologic Response (CA-125), Quality of Life, Resource utilization and PK DDI substudy.; time frame: 4 years

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
  •   Argentina
  •   Australia
  •   Austria
  •   Belgium
  •   Brazil
  •   Canada
  •   Chile
  •   France
  •   Germany
  •   Greece
  •   Hong Kong
  •   Hungary
  •   India
  •   Israel
  •   Italy
  •   Japan
  •   Korea, Republic of
  •   Mexico
  •   Netherlands
  •   Philippines
  •   Poland
  •   Portugal
  •   Russian Federation
  •   Singapore
  •   Spain
  •   Switzerland
  •   Taiwan, Province of China
  •   Ukraine
  •   United Kingdom
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2009/03/31
  •   1080
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- A histologically or cytologically confirmed diagnosis of non-mucinous epithelial
ovarian cancer including primary peritoneal or fallopian tube malignancies

- Must have measurable disease by CT or MRI scan

- Must have relapsed radiologically with a randomization date within ≥6 and < 24 months
of completion of first-line platinum chemotherapy

- Have been treated with debulking surgery and first-line platinum and taxane based

- Prior bevacizumbab maintenance is allowed. The last dose of bevacizumab must have
been at least 30 days before study Day 1. No cytotoxic maintenance therapy (e.g.
taxane) or cancer vaccine therapy is allowed.

- Must be a candidate for carboplatin and taxane therapy

- Neurologic function: neuropathy (sensory and motor) ≤CTCAE Grade 1

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Subjects who never responded to first-line platinum-based therapy or whose first
relapse occurs <6 months or >24 months from the last platinum therapy

- Subjects who have received other therapy to treat their ovarian cancer since relapse

- Known central nervous system (CNS) tumor involvement

- Evidence of other active invasive malignancy requiring treatment in the past 5 years

- Known allergic reaction to a prior monoclonal antibody therapy or have any documented

- Previous treatment with MORAb-003 (farletuzumab)

- Clinical contraindications to use of a taxane

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Morphotek
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up complete
  •   2013/05/01
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   4
  •   2013/10/30
* This entry means the parameter is not applicable or has not been set.